Registration
First Name
Last Name
Email
I consent to receive electronic messages regarding CADTH’s programs, including input and feedback opportunities, and other events as applicable.
Country
Canada
United States
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Cape Verde Islands
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos-Keeling Islands
Colombia
Comoros
Congo
Congo, Republic of (Brazzaville)
Cook Islands
Costa Rica
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Faeroe Islands
Falkland Islands
Fiji Islands
Finland
France
French Guiana
French Polynesia
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea (PRP)
Guinea-Bissau
Guyana
Haiti
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
Korea (North)
Korea (South)
Kuwait
Kyrgyz Republic
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali Republic
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte Island
Mexico
Micronesia, (Federal States of)
Moldova
Monaco
Mongolia
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Norway
Oman
Pakistan
Palau
Palestine
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Poland
Portugal
Puerto Rico
Qatar
Reunion Island
Romania
Russia
Rwanda
San Marino
Sao Tome and Príncipe
Saudi Arabia
Scotland
Senegal
Serbia
Seychelles Islands
Sierra Leone
Singapore
Slovak Republic
Slovenia
Solomon Islands
Somalia
South Africa
Spain
Sri Lanka
St. Helena
St. Kitts/Nevis
St. Lucia
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tokelau
Tonga Islands
Trinidad & Tobago
Tunisia
Turkey
Turkmenistan
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
Uruguay
US Virgin Islands
Uzbekistan
Vanuatu
Venezuela
Vietnam
Wallis and Futuna Islands
Western Samoa
Yemen
Zambia
Zimbabwe
Street
City
Province
State
Region
Alberta
British Columbia
Manitoba
New Brunswick
Newfoundland
Northwest Territories
Nova Scotia
Nunavut
Ontario
Prince Edward Island
Quebec
Saskatchewan
Yukon
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
District of Columbia
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming
Postal Code
Zip Code
Post Office code
Organization
Department
Job Title
Phone
Fax
Cell Phone
Public Profile
Type of Organization/Group
Review team and Committee members.
Drug Manufacturer/Tumour Group
– A drug manufacturer or designated consultant, or clinical and/or research group affiliated with a provincial/territorial cancer agency or Ministry of Health, eligible to file a Drug Submission.
Patient Group
– Eligible to provide input and feedback on a Drug Submission.
Clinicians
Additional Information for Patient Group
Section II
Organization Represents
Patients
Caregivers
Other (Please specify)
Organization Represents: Other
Number of Members
Primary Method of Contacting Members
Phone
Mail
E-Mail
Other (Please specify)
Primary Method of Contacting Members: Other
When was the organization established?
Mission Statement or Purpose of Organization
Section III
Organization Classification
Non-Profit
Registered Charitable Organization
Other (Please specify)
Organization Classification: Other
Potential Conflicts of Interest - financial support or grants from a pharmaceutical manufacturer, government or government agency?
Yes
No
Potential Conflicts of Interest - financial support from pharmaceutical manufacturers?
Yes
No
Please specify the name of the Pharmaceutical Manufacturer
Does the organization receive more than 50% of its operating funds from any single funder?
Yes
No
Section IV
Does the organization have a medical liason/lead?
Yes
No
Name of medical liason/lead
Additional Information for Clinicians
Section II
1. Please indicate your specialty. If applicable, please indicate your specific tumour site expertise (e.g., breast cancer, endocrine, gastrointestinal, etc.).
Breast Cancer
Endocrine Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecological Cancer
Head and Neck Cancer
Leukemia
Lung Cancer
Lymphoma
Myeloma
Neurological Cancer
Sarcoma
Skin and Melanoma
Other (Please specify):
2. Please indicate if you are an actively practising physician.
Yes
No
3. Please indicate if you are a member of a medical advisory board or a national or provincial medical organization (e.g., Communities Oncology Network).
Yes
No
If yes, please specify the name of the organization.
Section III
4. Potential Conflicts of Interest – have you been employed or engaged by a pharmaceutical manufacturer or a government or government agency within the past two (2) years?
Yes
No
If yes, please specify the name of the pharmaceutical manufacturer, a government or government agency.
IMPORTANT NOTE: To maintain the objectivity and credibility of CADTH's drug review processes, all participants in the CDR and pCODR review process must disclose any conflicts of interest as part of providing input and feedback on a drug review.
Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the input.
Enter the code word below.
reCAPTCHA validation is skipped. Set SkipRecaptcha property to false to enable validation.